Update: LexaGene completes alpha prototype
November 30, 2017
Today is the day we can proudly say that we have met our initial goal…as the instrument is finally assembled!
View press release here.
For the past year, we have been striving towards the goal of completing the development of our alpha prototype, which we expect will provide best-in-class detection capabilities once it is fully optimized. This milestone is the product of a lot of hard work and perseverance by some very talented people.
Our instrument has several features that make it unique and powerful. For example, we expect our instrument to be the first on the market that is easy-to-use and ‘open-access’. For the latter part, you may ask…what does that mean and why is it so important?
Let me explain. Currently, when someone is interested in detecting pathogens they have two options: 1) to manually perform the work using a highly skilled molecular biologist or 2) have an automated instrument process the sample using a pre-configured cartridge that detects one or several pathogens. The ‘pre-configured’ term means the manufacturer sells cartridges that only test for specified pathogens. This approach lacks flexibility. These systems are considered ‘closed-access’ – because they can only use pre-configured cartridges. So, if you are interested in detecting a pathogen (for example, Zika virus), but the manufacturer of your instrument doesn’t sell a Zika-specific cartridge, then you are out of luck and must manually process samples.
This is a big burden for many industries interested in pathogen detection, i.e. the biotech industry, food-safety testing, water quality monitoring, aquaculture pathogen surveillance, veterinarians, ER doctors and other clinicians, etc.
LexaGene’s open-access instrument is going to solve this problem since it will allow customers to purchase pathogen-specific tests from numerous vendors and these test reagents can be easily loaded onto LexaGene’s instrument for fully automated testing. This way, they can customize their testing to look for any pathogen(s) and/or antibiotic resistance gene(s) of interest. Also, our system is extremely flexible, allowing customers to screen for 1 – 22 targets at a time, which also enables scalable billing.
Another unique feature of our instrument is that it can process large volumes of sample, looking for those ultra-rare pathogens, which is very important in food safety testing, water quality monitoring, and of course … clinical diagnostics.
Last but not least, our time-to-result of just 1 hour, will enable customers to better manage the care of their patients and make decisions regarding the handling of potentially contaminated water or food items.
Taken together, we are very confident we are working on a winning solution.
Please stay tuned for updates.
Jack Regan, CEO, Founder